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Original article
Performing clinical 18F-FDG-PET/MRI of the mediastinum 
optimising a dedicated, patient-friendly protocol
Jurgen Peerlingsa,b,c,d, Leonie Paulisa, Cristina Miteaa,d, Frans Bakersa,  
Maaike Berbéeb, Roel Wiertsa, Stefan Vööa,e, Joachim Wildbergera,  
Aswin Hoffmannb,f,g,h, Philippe Lambinc,d and Felix Mottaghya,i        
Objective To construct a mediastinal-specific fluorine-
18-fluorodeoxyglucose (18F-FDG)-PET/MR protocol 
with high-quality MRI of minimal acquisition-time and 
comparable diagnostic value to 18F-FDG-PET/computed 
tomography (CT).
Materials and methods Fifteen healthy participants 
received PET/MRI and 10 patients with mediastinal 
tumours (eight non-small-cell lung, two oesophageal 
cancer) received 18F-FDG-PET/MRI immediately after 
18F-FDG-PET/CT. Sequences volume interpolated breath-
hold examination (T1-VIBE) and Half-Fourier acquisition 
single-shot turbo spin echo (T2-HASTE) were optimised 
by varying the parameters: breath-hold (BH, end-
expiration), fat suppression (spectral adiabatic inversion 
recovery), and ECG-triggering (ECG, end-diastole). Image 
quality (IQ) of each sequence-variation was qualitatively 
scored by medical experts and quantitatively assessed 
by calculating signal-to-noise ratios, contrast relative 
to muscle, standardized-uptake-value, and tumour-to-
blood ratios. Patient comfort was evaluated on patients’ 
experience. Diagnostic accuracy of 18F-FDG-PET/
MRI was compared to 18F-FDG-PET/CT, in reference to 
histopathology/cytopathology.
Results ECG-triggered T1-VIBE images showed the 
highest signal-to-noise ratio (P < 0.01) and the largest 
contrast between mediastinal soft-tissues, regardless 
of BH or free-breathing acquisition. IQ of ECG-triggered 
T1-VIBE scans in BH were scored qualitatively highest 
with good reader agreement (κ = 0.62). IQ of T2-HASTE 
was not significantly affected by BH acquisition (P > 0.9). 
Qualitative IQ of T1-VIBE and T2-HASTE declined after 
spectral adiabatic inversion recovery fat-suppression. All 
patients could maintain BH at end-expiration and reported 
no discomfort. Diagnostic performance of 18F-FDG-PET/
MR was not significantly different from 18F-FDG-PET/CT 
with comparable staging, standardized-uptake-values, and 
tumour-to-blood ratios. However, T-status was more often 
over-staged on 18F-FDG-PET/CT, while N-status was more 
frequently under-staged on 18F-FDG-PET/MR.
Conclusion ECG-triggered T1-VIBE sequences 
acquired during short, multiple BHs are recommended 
for mediastinal imaging using 18F-FDG-PET/MR. With 
dedicated protocols, 18F-FDG-PET/MRI will be useful in 
thoracic oncology and aid in diagnostic evaluation and 
tailored treatment decision-making.  Nucl Med Commun 
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Introduction
Hybrid imaging, combining PET with either computed 
tomography (i.e. PET/CT) or MRI (i.e. PET/MRI), has 
been implemented in a variety of oncological manage-
ment steps [1,2]. In thoracic oncological imaging, PET/
CT is considered to be the current clinical standard. 
Nevertheless, an additional MR scan is often needed 
to clarify equivocal findings, detect tumour infiltration, 
and differentiate metastatic lymph nodes (LNs) [3–5]. 
It was generally anticipated that with the development 
of integrated PET/MR systems, the diagnostic accuracy 
would improve for these situations. However, a clear 
clinical improvement of whole-body fluorine-18-fluo-
rodeoxyglucose (18F-FDG)-PET/MR over 18F-FDG-
PET/CT has yet to be determined in oncology [6]. An 
alternative approach using region-specific instead of 
whole-body 18F-FDG-PET/MRI-protocols could lead 
to more insight into the efficient application and further 
Supplemental Digital Content is available for this article. Direct URL citations 
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integration of PET/MR in thoracic oncological imaging. 
Here, PET-images could remain the leading diagnostic 
tool by detecting 18F-FDG-avid lesions with high sensi-
tivity, while MRI of 18F-FDG-positive regions would be 
better suited as the matching tool than CT to determine 
the underlying pathological correlate (e.g. tumour infil-
tration, mediastinal LN involvement, inflammation).
For new imaging modalities and protocols to be adopted 
an efficient patient workflow must be developed. Hybrid 
imaging protocol development rests on three fundamen-
tal pillars: (a) producing clinically valuable images with 
high image quality (IQ) and diagnostic accuracy, (b) 
implementing time-efficient protocols by simultaneous 
acquisition of PET and MRI, (c) efficient acquisition 
of complementary, nonredundant data [7]. For success-
ful mediastinal-specific protocols, also image-distorting 
MR-artefacts related to respiratory and cardiac motion 
need to be minimised using, for example, cardiac trigger-
ing and breath-hold (BH) techniques, while preserving 
patient comfort. However, patients with non-small-cell 
lung cancer (NSCLC) often present dyspnoea and may 
thus find it problematic to maintain a BH for a certain 
period of time. Therefore, MRI sequences have to be tai-
lored to this specific patient population.
To this end, the goal of this study was to obtain a medi-
astinal-specific clinical 18F-FDG-PET/MR protocol 
containing dedicated MRI-sequences able to produce 
high-quality images with optimal patient compliance and 
diagnostic performance comparable to 18F-FDG-PET/
CT. The different T1-weighted/T2-weighted sequences 
will not be compared with each other. Functional MRI 
sequences, such as diffusion-weighted (DW) MRI, will 
not be assessed in this study but might benefit future 
clinical protocols.
Materials and methods
Study population
Between June 2016 and February 2017, 25 participants were 
included for PET/MRI after approval by the local Ethics 
Review Committee (METC 16-4-036). Fifteen adults, 
healthy volunteers were included to optimise clinical MRI 
pulse-sequences for imaging mediastinal structures without 
acquiring PET-images. Next, 10 patients suspected of hav-
ing mediastinal malignancies (NSCLC n = 8, oesophageal 
cancer; EC n = 2) were included to validate the optimised 
protocol. All patients received a conventional 18F-FDG-
PET/CT scan for primary staging, immediately followed by 
a dedicated 18F-FDG-PET/MRI scan.
Image acquisition
18F-FDG-PET/CT imaging
Whole-body PET images were obtained on a Gemini TF 
64 scanner (Philips Healthcare, Best, NL and Labrador, 
USA) using the default manufacturer’s time-of-flight 
reconstruction algorithm (BLOB-OS-TF). The injected 
dose of 18F-FDG was 2 MBq/kg (162 ± 34 MBq) and 
administered after patients fasted for 4 h. CT images of 
4 mm thickness were acquired at 120 kV and 30 mAs.
18F-FDG-PET/MRI
Mediastinal PET/MRI was performed on a 3-Tesla 
Magnetom Biograph mMR scanner (Siemens 
Healthineers, Erlangen, Germany) using two body coils. 
18F-FDG-PET data was acquired in list-mode for 15 min 
at one bed-position. PET-images were reconstructed 
using a 3D-iterative ordinary Poisson ordered-subsets 
expectation maximisation (OP-OSEM3D) reconstruc-
tion algorithm (3 iterations, 21 subsets, 4 mm Gaussian 
smoothing) and fused with MRI using Syngo.via software 
(Siemens Healthcare). The dedicated PET/MR-protocol 
was centred over the carina and included a standard 
localizer sequence, followed by a 3D low-resolution 
T1-Dixon-VIBE sequence for MR-based attenuation 
correction. The IQ and diagnostic value of T1-Dixon-
VIBE sequence have not been assessment in this study 
[21]. Based on literature and preliminary evaluation 
of clinically available sequences, two sequences were 
selected for further optimisation for tumour imaging: 
(a) T1-weighted Volumetric Interpolated 3D Gradient 
Echo (T1-VIBE) and (b) T2-weighted Half Fourier 
Acquisition Single Shot Turbo Spin Echo (T2-HASTE) 
(Table  1) [8–10]. Sequences were optimised to acquire 
transversal images of high spatial resolution (in-plane res-
olution < 1.6 mm for LN detection) within a reasonable 
acquisition time [11].
Variations of mediastinal-specific MR scanning
Images were acquired using all combinations of MR 
settings: (a) free-breathing (FB) or BH acquisition, (b) 
with or without ECG-triggering, (c) with or without fat 
suppression.
BH scans were performed in multiple sessions of 
four times 5.7 s for T1-VIBE and seven times 8.1 s for 
T2-HASTE.
Table 1  Details of PET/MRI sequences
Parameters T1-VIBE T2-HASTE
Sequence type Gradient-echo Spin-echo
Acquisition 3D 2D
Image plane Transversal Transversal
TR (ms) 3.64 1500
TE (ms) 1.23 113
Flip angle (deg.) 9 90
Number of slices 48 48
Slice thickness (mm) 4 5.5
Distance factor (%) 0 0
Field of view 400 × 262 450 × 450
Matrix (reconstructed) 189 × 384 259 × 320
Resolution (mm) 1.4 × 1.0 × 4 1.7 × 1.4 × 5.5
Bandwidth (Hz/pixel) 592 710
Echo train length 1 256
Parallel imaging GRAPPA 2 GRAPPA 2
TA (s) 5.7 ( × 4)a 8.1 ( × 7)a
T2-HASTE, Half-Fourier acquisition single-shot turbo spin echo; T1-VIBE, 
T1-weighted Volumetric Interpolated 3D Gradient Echo.
aTA measured during single breath-hold.
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ECG-triggering was used to synchronise MR signal acqui-
sition to the cardiac cycle by real-time R-wave detection. 
However, ECG-triggering is only effective when images 
were acquired during the diastolic phase with minimal 
pulsatile motion. Effective ECG-triggering in diastole 
was not possible within the desired acquisition time for 
T2-HASTE and fat-suppressed T1-VIBE using spectral 
adiabatic inversion recovery (SPAIR), and thus has not 
been evaluated for these sequence-variants.
Data analysis
Quantitative image analysis
Volumes-of-interest (VOIs) were established by deline-
ating mediastinal structures (i.e. adipose tissue, muscles, 
bone, oesophagus, lung, and liver) and tumorous lesions. 
All VOIs had the same size of 1.6 cm3 and were placed 
over three slices around the level of the carina. To quan-
tify IQ, signal-to-noise ratio (SNR) and contrast ratio rela-
tive to the muscle (CR) were calculated using Eqs (1 and 
2), respectively.
   SNR=
SI
0.655 SD
tissue
noise×
,  (1)
  CR=
SI
SI
tissue
muscle
,  (2)
SI
tissue
 and SI
muscle
 represented the measured signal inten-
sities of delineated tissues and muscle, respectively [12]. 
The Rayleigh-distribution in noise outside the body was 
accounted for in the SD (SD
noise
) [12]. Tissue visibility 
and contrast between adjacent tissues were quantified by 
differences in CR of the aforementioned tissues (ΔCR).
On 18F-FDG-PET/MRIs, 18F-FDG-avid lesions were 
manually delineated and maximal and mean standard 
uptake values (SUVs) were obtained. Tumor-to-blood 
ratios (TBRs) were calculated from 18F-FDG-activity of 
delineated lesions and aortic blood.
Qualitative image analysis
Two clinical experts in thoracic oncological imaging (radi-
ologist F.B., and radiation-oncologist M.B.) independently 
rated the MRI quality using a five-point scoring scale 
(Supplementary Appendix Table A1, Supplemental digi-
tal content 1, http://links.lww.com/NMC/A145). A score of 1 
represented poor IQ, not suitable for clinical use, while a 
score of 5 represented high IQ.
Clinical validation
Patient compliance and comfort
Patient compliance was based on the ability to follow and 
maintain BH instructions at end-expiration and the abil-
ity to remain lying still during scanning. Comfort during 
scanning was evaluated by enquiring the emotional sta-
tus of all participants (feelings of stress, claustrophobia, 
physical discomfort from laying still or acoustic noise) 
and their perception of scan-time (BH duration, resting 
periods between BHs, and total scan duration).
Diagnostic performance
While blinded from clinical data, independent reviewers 
randomly evaluated the diagnostic value of all 18F-FDG-
PET/MRI and 18F-FDG-PET/CT images according to 
the AJCC/UICC TNM-system with corresponding stage 
grouping (7th ed.). M-stage was evaluated on whole-body 
PET/CT and on thoracic PET/MRIs. Clinical reports 
with diagnoses based on PET/CT and histopathologic/
cytopathologic analyses after mediastinoscopy or ultra-
sound-guided transbronchial needle aspiration were 
obtained as part of standard clinical care and served as 
the golden standard for further reference. All PET/MRI 
analyses were performed using OsiriX software (Pixmeo 
Sarl, Bernex, Switzerland).
Statistical analysis
Firstly, for protocol-optimisation statistical differences 
between volunteer and patient data in SNR of normal tis-
sue was tested using a paired Student t-test. Populations 
were pooled when no significant differences were appar-
ent. Secondly, differences in SNR and CR between 
sequence-variations were tested for statistical signifi-
cance using two-way analysis of variance with Tukey cor-
rection, respectively. Thirdly, differences in CR between 
tumour/LN and adjacent tissue were statistically tested 
per sequence-variation using two-way analysis of vari-
ance with Tukey correction to quantify contrast between 
tissues, and tumour visibility, relative to muscle-tissue. 
Finally, reader agreement in qualitative image assess-
ment was analysed using weighted κ reliability statistics 
(κ < 0.2 = slight agreement, κ = 0.2–0.4 = fair, κ = 0.41–
0.6 = moderate, κ = 0.6–0.8 = good, κ > 0.8 = excellent).
For clinical validation in patients, we first tested the 
hypothesis that there is no statistically significant differ-
ence in SUV
mean
, SUV
max
, and TBR acquired on PET/
MRI and PET/CT using a paired Student t-test and a 
Bland–Altman plot. The diagnostic performances of PET/
MR and PET/CT (i.e. TNM staging) were compared in 
terms of sensitivity and specificity using a McNemar test. 
All statistical analyses were performed using GraphPad 
Prism v6.01 (GraphPad, California, USA). P values less 
than 0.05 were considered statistically significant.
Results
MR-protocol optimisation for mediastinal imaging
Quantitative image analyses
For T1-VIBE and T2-HASTE, SNRs of healthy par-
ticipants and patients were not significantly different 
(P = 0.52 and 0.065). In tumorous lesions, SNR was 
only significantly different between T1-VIBE BH with 
and without ECG-triggering (P = 0.030). In 18F-FDG-
avid LN, no significant difference was found between 
T1-VIBE sequence-variants (P > 0.05). In the pooled 
population of volunteer and patient data, there were no 
statistically significant differences between T1-VIBE 
sequences acquired in BH and FB (P > 0.05). However, 
the addition of ECG-triggering to either T1-VIBE BH or 
Copyright © 2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
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FB sequence-variations resulted in significantly greater 
SNR for all soft-tissue structures of the mediastinum 
(P ≤ 0.001). However, ECG-triggering not significantly 
affect the SNR of bone structures (P = 0.76 and 0.73) and 
lung tissue (P ≥ 0.99 and P = 0.998), respectively (Fig. 1a). 
The addition of SPAIR to T1-VIBE BH or T1-VIBE FB 
did not result in statistically significant differences in 
SNR (P > 0.1).
In T2-HASTE images, SNR was unaffected by BH 
compared to free breathing for all tissues (P > 0.97). The 
addition of SPAIR fat-suppression to T2-HASTE BH 
and T2-HASTE FB significantly reduced quantitative 
SNR in adipose tissue (P ≤ 0.0001 and  ≤ 0.0001) and bone 
(P = 0.0236 and 0.0197), but remained unaffected for all 
other tissues. These findings concerning the SNRs of 
various tissues for each sequence-variation are presented 
in Supplementary Appendix Fig. A1 (Supplemental digi-
tal content 2, http://links.lww.com/NMC/A146).
Contrast within images indicated the ability to differ-
entiate various tissues from SI
muscle
 (Fig.  1). CR-values 
were not significantly different between T1-VIBE and 
between T2-HASTE sequence-variants (P > 0.9), except 
between sequences acquired with and without SPAIR 
fat-suppression (P < 0.0001). However, within T1-VIBE 
sequence-variants contrast between adjacent tissues 
(ΔCR) was significant between oesophagus, lung, and fat 
(P ≤ 0.0001), between lung, bone, and liver (P ≤ 0.0001), 
and between tumour and fat (P ≤ 0.0001). In ECG-
triggered T1-VIBE sequences, ΔCR was also significant 
between oesophagus and bone (P < 0.05), and between 
tumour and lung (P < 0.05). The addition of SPAIR did 
not result in additional significant results of ΔCR. For 
T2-HASTE BH and T2-HASTE FB, ΔCR was signif-
icant between lung, oesophagus (P = 0.013 and 0.008), 
and bone (P = 0.0008 and 0.0012) and between fat and 
all other tissues (P ≤ 0.0001). When fat was suppressed 
by SPAIR, no significant differences in contrast were 
observed. In addition, differences in SNR and CR can 
be appreciated and the visibility of mediastinal tissues 
and cancerous lesions can be deduced for each T1-VIBE 
sequence-variant (Fig. 1). Tumour visibility was highest 
in ECG-triggered T1-VIBE sequences acquired in BH 
(SNR = 62.6, CR = 0.86), followed closely by T1-VIBE 
ECG FB (SNR = 59.2, CR = 0.83). However, the overall 
IQ and visibility of all mediastinal structures are deter-
mined by the balance of SNR and ΔCR, which is demon-
strated by the spread between data-points and the slope 
of the plots in Fig. 1. Visibility of all mediastinal struc-
tures was lower in T1-VIBE sequences acquired without 
ECG-triggering and further decreased in fat-suppressed 
sequences, which presented more clustering of data-
points and a lower slope. For T2-HASTE sequences, an 
acceptable distribution of SNR-CR data points was noted 
(Supplementary Appendix Fig. A1, Supplemental digital 
content 2, http://links.lww.com/NMC/A146). However, no 
differences between sequence-variants were evident.
Qualitative image analyses
T1-VIBE and T2-HASTE IQ showed good inter-reader 
agreement (κ=0.617 and 0.625, respectively; Table 2 and 
Fig. 2). For T1-VIBE, qualitative IQ was scored highest 
for images acquired during BH and with ECG-triggering 
and contained a homogeneous distribution of SI within 
VOIs and visually less noise. T1-VIBE BH ECG showed 
clear organ-edge detection with low incidences of arte-
facts at the mediastinum. In FB ECG-triggered T1-VIBE 
images more motion artefacts were present at the medi-
astinum, leading to qualitatively moderate IQ.
Generally, the IQ of T2-HASTE images was scored 
lower than T1-VIBE images. Moderate IQ was registered 
for both T2-HASTE BH and FB sequence-variants with 
moderate contouring of mediastinal structures. However, 
a notable increase in IQ of T2-HASTE was perceived 
towards abdominal regions (e.g. gastroesophageal junc-
tion, liver).
For both T1-VIBE and T2-HASTE, SPAIR adequately 
suppressed fat near the mediastinum. However, the addi-
tion of SPAIR visually increased image noise and led to 
poor IQ, making it difficult to detect and differentiate 
mediastinal structures.
Clinical validation
Patient compliance and comfort
All included participants successfully underwent PET/
MRI and were able to maintain BHs at end-expiration for 
all sequences (Table 3). However, patients with mediasti-
nal malignancies had more trouble complying to scanning 
instructions and reported that the repetition frequency 
of multiple BHs made it increasingly difficult to con-
sistently maintain BH. The BH-duration of 8.7 s during 
T2-HASTE image acquisition was perceived as nearing 
the patients’ limits. Longer BHs, more BH repetitions, or 
the use of single BH schemes are therefore unlikely to 
be successful in patients with mediastinal malignancies. 
After optimisation, the total scan duration was 15–20 min 
and no excessive physical or psychological discomfort 
was reported.
PET-image quality
The radioactive dose at the start of 18F-FDG-PET/CT 
was 105 ± 33 MBq at 65 ± 10 min postinjection and 71 ± 21 
MBq at the start of 18F-FDG-PET/MR (127 ± 19 min 
postinjection) (Table  3). Despite different attenua-
tion-correction methods, no significant differences were 
found between modalities in SUV
mean
 and SUV
max
 for 
18F-FDG-avid tumours (P = 0.736 and 0.177) and suspi-
cious LNs (P = 0.184 and 0.535), respectively. Likewise, 
TBR-values of PET/MR was not significantly different 
from PET/CT for 18F-FDG-avid tumours (P = 0.082) 
and suspicious LNs (P = 0.125). Potentially, the delay in 
injection time was compensated by the extended PET-
acquisition time for the PET/MR protocol compared to 
the clinical PET/CT protocol.
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Fig. 1
Quantitative analyses of T1-VIBE image quality acquired in cancer patients (n=10, eight primary tumours, five LN metastases) by assessment 
of signal-to-noise ratio (SNR) and contrast ratio (CR) per sequence-variant over different tissues. VOIs were drawn over target regions and 
background-regions located outside the body. LN, lymph node; T2-HASTE, Half-Fourier acquisition single-shot turbo spin echo; T1-VIBE, 
T1-weighted Volumetric Interpolated 3D Gradient Echo.
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Subjective assessment of PET-images indicated clinical-
ly-acceptable IQ and excellent alignment with the ana-
tomical substrate on MRI and CT, respectively. Generally, 
lesions could be well differentiated with slightly blurred 
lesion edges on PET/MRIs. In patients 3 and 4, consid-
erable blurring resulted in the uncertain definition of 
18F-FDG-avidity and lesion differentiation.
Diagnostic performance
No significant differences in sensitivity and specificity on 
defining T-stage (P > 0.99) or N-stage (P > 0.99) was pre-
sented between PET/MR and PET/CT, compared with 
histopathological/cytopathological analyses. However, 
T-status was more often over-staged on 18F-FDG-PET/
CT (3/10 patients) and N-status was more frequently 
under-staged on 18F-FDG-PET/MR (2/5 patients) 
(Table 4 and Figs 3 and 4). In patient 5 and 7, M-status 
were accurately evaluated on both whole-body 18F-FDG-
PET/CT and thorax 18F-FDG-PET/MRIs.
Discussion
In this study, we presented a clinically-manageable, 
region-specific PET/MR protocol with high patient 
compliance and stable MR pulse sequences that consist-
ently produce images of high IQ and diagnostic accuracy, 
within a reasonable acquisition time. This carefully-opti-
mised PET/MR protocol has led to less over-staging than 
PET/CT alone and establishes an important region-spe-
cific use in the patient workflow.
Based on qualitative and quantitative image analyses, 
T1-VIBE and T2-HASTE were adequate sequences 
for mediastinal MRI and tumour visualisation. For BH 
or FB T1-VIBE, no significant differences were found 
in SNR and CR between images acquired with or with-
out SPAIR. Although SPAIR performed well at fat sup-
pression in all sequences, organ-edges became blurred 
which made visually differentiating mediastinal struc-
tures more difficult. In contrast, the addition of ECG-
triggering to either BH-variant or FB-variant resulted in 
a significant increase in quantitative IQ, indicating that 
ECG-triggering had the most impact on IQ by reducing 
the effect of cardiac and aortic motion during scanning. 
As such, ECG-triggered T1-VIBE presented high con-
trast between adjacent tissues and ease of differentiat-
ing tumours and metastatic LNs, relative to muscle. The 
application of ECG-triggered T1-VIBE could be espe-
cially useful in assessing mediastinal tumours with infil-
trates into the pericardium or large vessels [11]. However, 
ECG-triggering might be inefficient in patients with 
arrhythmia or complex QRS-patterns.
Qualitative assessment of ECG-triggered T1-VIBE indi-
cated a slight preference for BH-sequences as fewer 
image-distorting MR-artefacts were present at the medi-
astinum. By maintaining BH at end-expiration, mean dia-
phragm motion is more stable (0.15 mm/s) compared to 
end-inspiration BH (0.1–7.9 mm/s) [13]. This recommen-
dation is in contrast to the suggested protocol of Biederer 
et al. [11,14] that contain end-inspiration BH instructions 
of 20 s. However, ample time between BH-intervals is 
needed to avoid fatigue and failure to maintain reproduc-
ible BHs. Therefore, short, multiple BHs are preferred 
without tiring the patient. When a patient is unfit to per-
form these BHs, a FB ECG-triggered T1-VIBE could 
still produce adequate images for clinical use. In this, 
however, motion artefacts would appear more frequent. 
Alternatively, the respiratory motion could be handled 
by automated respiratory triggering or gated acquisition 
using a navigator sequence to monitor the diaphragm’s 
position [15–17]. However, these techniques are not flaw-
less in compensating motion artefacts and will extend the 
total scan duration [11]. In literature, T1-VIBE has been 
shown to be robust in the presence of cardiac pulsation, 
able to identify small pulmonary nodules, and has been 
promoted for thoracic imaging [8,10,18]. For T2-HASTE, 
quantitative and qualitative IQ was unaffected by acqui-
sition in BH or FB. However, lengthy BH-durations were 
not patient friendly and prolonged acquisition-time. 
T2-HASTE acquisition in FB might, therefore, be pre-
ferred in clinical practice. Previous studies recommended 
applying fat saturation in contrast-enhanced MRI to dif-
ferentiate mediastinal LNs from the surrounding fat 
[10,11,19]. However, in this study, no contrast agent was 
used and the addition of SPAIR did not significantly 
affect SNR and contrast between tumours, LN, and sur-
rounding tissue. Nevertheless, unenhanced T2-HASTE 
sequences have been reported to sensitively detect pleu-
ral effusion and intra-atelectatic tumour growth [9,20,21]. 
The effect of motion and MR motion-correction was less 
prone on PET-images, although motion has a negative 
effect on the localisation of PET-signal.
In this study, the diagnostic performance of 18F-FDG-
PET/MR was not inferior to 18F-FDG-PET/CT in 
Table 2 Qualitative assessment of MRI quality assessed in 
healthy volunteers and patients using a five-point scoring scale 
(score 1 = low image quality, score 5 = high image quality)
Qualitative five-point scoringa
Sequence R
1
R
2
κ
T1-VIBE   0.617
 BH 2 ± 0.5 3 ± 0.4  
 BH-ECG 4 ± 0.5 4 ± 0.3  
 BH-SPAIR 2 ± 0.5 2 ± 0.5  
 FB 2 ± 0.5 3 ± 0.5  
 FB-ECG 3 ± 0.0 3 ± 0.3  
 FB-SPAIR 2 ± 0.6 2 ± 0.5  
T2-HASTE   0.625
 BH 3 ± 0.5 3 ± 0.3  
 BH-SPAIR 2 ± 0.3 2 ± 0.3  
 FB 2 ± 0.6 3 ± 0.5  
 FB-SPAIR 2 ± 0.4 2 ± 0.3  
BH, breath-hold; FB, free-breathing; SPAIR, spectral adiabatic inversion recov-
ery; T2-HASTE, Half-Fourier acquisition single-shot turbo spin echo; T1-VIBE, 
T1-weighted Volumetric Interpolated 3D Gradient Echo.
aQualitative five-point scoring system is presented in Supplementary Appendix 
Table A2 (Supplemental digital content 1, http://links.lww.com/NMC/A145).
Copyright © 2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
Mediastinal PET/MRI in clinical oncology Peerlings et al. 821
defining tumour or LN status. SUV
mean
 and SUV
max
 
were not significantly different between 18F-FDG-PET/
MR and 18F-FDG-PET/CT meaning that the measured 
PET-values were not affected by the applied attenua-
tion correction technique for each modality, respectively. 
In T-staging, pleural infiltration of NSCLC (Fig. 4) and 
Fig. 2
T1-VIBE (a) and T2-HASTE (b) images acquired in healthy volunteers at varying patient-specific parameters [in breath hold (BH), in free-breathing 
(FB), and with/without ECG-triggering, or SPAIR fat suppression]. T2-HASTE, Half-Fourier acquisition single-shot turbo spin echo; T1-VIBE, 
T1-weighted Volumetric Interpolated 3D Gradient Echo.
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thickening of oesophageal wall layers in EC (Fig. 3c–f) 
could be better detected on high-resolution MRI, result-
ing in less over-staging compared to 18F-FDG-PET/
CT (Fig. 3a and b) [3,15,22]. In N-staging, contradicting 
results of diagnostic performance have been reported in 
single-injection 18F-FDG-PET/CT versus 18F-FDG-
PET/MR studies. In EC, Lee et  al. [22] showed that 
PET/MR presented the highest diagnostic performance 
for T-staging, followed by EUS, PET/CT and CT. In 
agreement to our study, however, these authors demon-
strated no significant differences in diagnostic accuracy 
for diagnosing nodal metastasis. In NSCLC, no clear (dis)
advantage of 18F-FDG-PET/MR over 18F-FDG-PET/
CT is determined in TNM-staging or therapeutic deci-
sion-making [23–25]. Heusch et al. [26] showed no differ-
ence in T-staging or N-staging NSCLC with sensitivity, 
specificity, and accuracy (P = 0.48). However, fewer over/
under-staging (9%) were discovered using 18F-FDG-
PET/MR, which concurred to our findings. In our study, 
18F-FDG-PET/MR produces clinically acceptable 
images from simultaneously acquired PET and MR-data 
of similar value as the clinically standard 18F-FDG-PET/
CT [24,26,27]. In addition, 18F-FDG-PET/MRIs could 
be clinically valuable by detecting tumour infiltration in 
adjacent organs. However, the impact of mediastinal-spe-
cific 18F-FDG-PET/MRI on TNM-staging needs to be 
investigated further in large-scale studies.
This study is limited in patient population and in the 
diversity of MR-sequences tested. We selected conven-
tional, clinical T1-weighted and T2-weighted sequences 
and did not alter sequence-parameter settings while 
testing the aforementioned sequence-variables. In some 
patients, the gastroesophageal junction was not depicted 
due to the limited field-of-view of T1-VIBE. For a future 
depiction of EC, cranio-caudal field-of-view-settings 
need to be adjusted to extent from commonly affected 
cervical to coeliac LN-stations in EC. Alternative 
sequences to T1-VIBE (radial-VIBE, CAIPIRINHA-
VIBE, contrast-enhanced VIBE) have been previously 
Table 3 Patient information and quantitative analyses of 18F-FDG-PET image quality of both PET/CT and PET/MRI modalities
  Primary tumour Lymph node
Patient 18F-FDG dose (MBq) Corrected dose (MBq) SUV
max
SUV
mean
  ± SD TBR SUV
max
SUV
mean
  ± SD TBR
PET/CT
 1 234.2 153 9.0 5.1 ± 1.9 2.8 – – –
 2 152.4 98 0.8 0.6 ± 0.1 0.4 – – –
 3 164.1 110 4.1 2.4 ± 0.9 1.6 – – –
 4 116 68 1.0 0.7 ± 0.2 0.5 2.2 1.6 ± 0.4 1.2
 5 208.9 150 13.8 10.2 ± 2.2 5.3 5.6 3.5 ± 1.2 1.8
 6 163.3 70 No tumour – – – – –
 7 139.75 98 9.0 7.7 ± 0.7 4.4 8.3 5.0 ± 1.5 2.2
 8 142.4 97 No tumour – – – – –
 9 147.8 100 25.2 16.2 ± 3.3 13.9 2.9 2.0 ± 0.5 1.7
 10 150.1 63 9.7 4.6 ± 2.1 4.1 4.9 3.3 ± 0.9 2.9
PET/MR
 1 234.2 116 13.0 6.8 ± 2.6 4.5 – – –
 2 152.4 59 0.9 0.6 ± 0.15 0.6 – – –
 3 164.1 71 6.8 3.5 ± 1.5 2.1 – – –
 4 116 50 1.0 0.5 ± 0.2 0.6 2.7 1.6 ± 0.6 1.9
 5 208.9 100 21.2 9.7 ± 5.5 5.9 6.5 4.2 ± 1.4 2.5
 6 163.3 55 No tumour – – – – –
 7 139.75 65 10.5 7.41 ± 1.28 1.3 7.8 4.8 ± 1.3 4.3
 8 142.4 58 No tumour – – – – –
 9 147.8 73 24.1 17.2 ± 3.2 20.1 2.9 2.0 ± 0.5 2.7
 10 150.1 59 7.6 3.5 ± 1.8 3.3 2.6 2.2 ± 0.4 2.1
Maximal and mean standardized uptake value (SUV
max
 and SUV
mean
) were measured over tumour regions. Tumour-to-blood uptake ratio (TBR) was based on SUV
mean
 of 
tumour regions and venous blood pools.
CT, computed tomography; 18F-FDG, fluorine-18-fluorodeoxyglucose.
Table 4  Patient information and diagnostic performance 
(pathological and clinical TNM staging) based on PET/CT and 
PET/MRI
   Diagnosis
Patients no. Cancer Sex Age 18F-FDG-PET/CT Clinical report
1 EC Male 80 pT1N0 cT2N0M0
2 NSCLC Female 54 pT0N0 cT1aN0M0
3 NSCLC Male 64 pTxN0 cT0N0M0
4 NSCLC Male 41 pTxN0 cT0N0
5 NSCLC Male 70 pT4N2M1 cT2bN2M1a
6 NSCLC Female 74 pT0N0 cT0N0
7 NSCLC Male 71 pT4N3M1 cT4N3M1b
8 NSCLC Female 52 pT0N0 cT0N0
9 NSCLC Male 63 pT4N0-2 cT4N2M0
10 EC Male 70 pTxN1 cT3N1M0
Patients no. Cancer Sex Age 18F-FDG-PET/MR Clinical Report
1 EC Male 80 pT2N0 cT2N0M0
2 NSCLC Female 54 pT1N0 cT1aN0M0
3 NSCLC Male 64 pTxN0 cT0N0M0
4 NSCLC Male 41 pTxN2 cT0N0
5 NSCLC Male 70 pT2N1M1 cT2bN2M1a
6 NSCLC Female 74 pT0N0 cT0N0
7 NSCLC Male 71 pT4N3M1 cT4N3M1b
8 NSCLC Female 52 pT0N0 cT0N0
9 NSCLC Male 63 pT3N1 cT4N2M0
10 EC Male 70 pT2N1 cT3N1M0
CT, computed tomography; 18F-FDG, fluorine-18-fluorodeoxyglucose; NSCLC, 
non-small-cell lung cancer.
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Fig. 3
18F-FDG-PET/CT (a, b) and 18F-FDG-PET/MRI (c–f) of patient 1 (male, 68 years) with oesophageal cancer (white triangle). Fused images (b, d, f) 
are respectively compiled of thoracic CT (a), T1-VIBE BH ECG (c), and T2-HASTE BH (e). BH, breath hold; CT, computed tomography; 18F-FDG, 
fluorine-18-fluorodeoxyglucose; T2-HASTE, Half-Fourier acquisition single-shot turbo spin echo; T1-VIBE, T1-weighted Volumetric Interpolated 3D 
Gradient Echo.
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studied and could potentially improve mediastinal 
imaging [28]. Radial-VIBE is less susceptible to respira-
tory-motion artefacts and showed high overall IQ in pae-
diatric abdominal MRI [29]. However, this experimental 
sequence is prone to streaking artefacts and not standard-
ly-available on PET/MR-systems [30]. CAIPIRINHA-
VIBE has been shown to produce abdominal and thoracic 
images with higher SNR and spatial resolution compared 
to T1-VIBE by improving parallel imaging and reducing 
aliasing artefacts [31].
For successful clinical imaging, PET/MR protocols 
need to be developed for time-efficient, region-specific 
acquisition of high-quality images [7,32]. Efficient PET/
MR protocols could be expanded with DW MRI, steady-
state free precession or inversion recovery sequences that 
have proven to be clinically useful in EC and NSCLC 
[10,33,34]. However, several studies suggest an overlap 
in metabolic activity and tumour-cellularity as assessed 
by 18F-FDG-PET and DW-MRI, respectively [35,36]. 
Acquisition of time-consuming DW-MRI is only worth-
while when truly synergistic information could be gained 
for either diagnostics or treatment-decision making [6,37]. 
Therefore, efficient PET/MR protocols may need to com-
bine anatomical and functional MRI with PET-imaging 
Fig. 4
18F-FDG-PET/CT (a, b) and 18F-FDG-PET/MRI (c, d) of patient 5 (male, 70 years) with non-small-cell lung cancer (NSCLC) and thoracic 
metastases (white triangles). Tumour infiltration was dismissed on ECG-triggered T1-VIBE images acquired in breath-hold (b). 18F-FDG,  
fluorine-18-fluorodeoxyglucose; T1-VIBE, T1-weighted Volumetric Interpolated 3D Gradient Echo.
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that uses radioactive tracers beyond 18F-FDG, such as 
18F-HX4 (i.e. hypoxia imaging), but reserve 18F-FDG (i.e. 
glucose metabolism) for PET/CT that is already well-in-
tegrated in clinical practice and holds great diagnostic 
value. In radiation therapy, PET/MRIs could be valuable 
in precisely differentiating malignant lesions from organs-
at-risk, defining the metabolic phenotype of mediastinal 
tumours, and defining treatment strategies. The search for 
key applications of PET/MR needs to be further stimu-
lated to work towards personalised patient care [38–41].
Conclusion
A region-specific PET/MRI protocol, including T1-VIBE 
ECG and T2-HASTE, can be used for dedicated medi-
astinal examinations and produce images with acceptable 
quality that is both patient-friendly and potentially clini-
cally valuable in thoracic oncology.
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